samedan logo
 
 
 
spacer
home > ebr > spring 2003 > absolute or limited product protection for biotech inventions
PUBLICATIONS
European Biopharmaceutical Review

Absolute or Limited Product Protection for Biotech Inventions

In the first part of this article, which appeared in the Winter 2002 issue of EBR, Dr Uta Köster investigated the pros and cons of absolute product protection against the background of the ongoing debate on the implementation of EC Directive 98/44 on the protection of biotechnological inventions (BIO-DIR) in Germany. Possible repercussions on pharmaceutical and biological R&D, as well as transferability to gene patents, were discussed with regard to relevant case law and the principles of patent law.

In Part II, a comparative analysis of the respective national laws and regulations within the EC and the US is followed by a critique of the different legal circumstances of enforcement/infringement, as related to absolute product protection versus protection limited to functions. A focus on the current granting practice of the EPO for biotechnology patents and medical applications concludes Part II.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Uta Kцster, Associate with Bardehle Pagenberg

Dr Uta Kцster is an Associate with the Munich-based intellectual property law firm Bardehle Pagenberg Dost Altenburg Geissler. The firm provides the combined services of patent attorneys and attorneys-at-law, offering prosecution, litigation and counselling in all matters related to intellectual property, covering all fields of technology.

Dr Kцster is an Attorney-at-Law with a doctorate degree in Biology. She is active in counselling and litigation, with a practice focus on patent law, in particular biotechnology patents.

spacer
By Dr Uta Kцster
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Qatar Airways Becomes Largest Passenger and Cargo Airline Globally Despite the Illegal Blockade and COVID-19 Crisis

Airline’s resolve to continue operating and growing over the last three years in the face of the illegal blockade has enabled the airline to succeed during the COVID-19 crisis The Best Airline in the World has built strong levels of trust with passengers and governments around the world for continuing to operate to take people home and its leadership on safety measures Hamad International Airport, The Best Airport in the Middle East, leads the way with strong levels of customer service while implementing the latest technologies to optimise passenger and employee safety
More info >>

White Papers

Translating Cancer Genomics Into A Personalised Approach For Cancer Patients

PRA Health Sciences (PRA)

Over the past few decades, the approach to prevention, diagnosis and treatment of cancer has radically shifted from organ-based to morphology-based and most recently, to genetics-based. Personalized or precision medicine (tailoring a treatment for a patient’s particular disease at a precise time point) is being performed every day at different levels in the clinical setting.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement